Lake's Advantage 24 contraceptive is outside OTC review -- FDA warning letter.
This article was originally published in The Tan Sheet
Executive Summary
"24-HOUR" CLAIM PUTS ADVANTAGE 24 CONTRACEPTIVE OUTSIDE OTC REVIEW, FDA told Lake Pharmaceuticals in a warning letter dated Sept. 5, 1995 but only recently released by the agency. The claim for the nonoxynol-9-containing product that its "patented bioadhesive gel...ensures that the spermicide remains in place...for up to 24 hours" distinguishes Advantage 24 from shorter-duration N-9 products currently included in the OTC vaginal contraceptives monograph, according to the agency.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning